药学英语电子教案课件

单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,*,Foreign Investment In Chinese,Pharmaceutical,Sector,Foreign Investment In Chinese,pharma-,词缀：,Pharmaceutic,Pharmacology:biology,Pharmacist,：,Scientist,chemist,pharma-词缀：Pharma,Despite problems of cultural,ethical and regulatory differences,a growing number,of foreign companies have begun,multicentre,Phase III clinical trials,in China.,Despite problems of c,Clinical trials,Clinical trial Phase,:,healthy subjects:,effects on body functions,dose definition,pharmacokinetics,Clinical trial phase,:,selected patients:,effects on disease;safety,efficacy,dose,pharmacokinetics,Clinical trial phase,:,patient groups:,comparison with standard therapy FDA approval,Clinical trial phase,:,general use:,long-term benefit-risk evaluation,Clinical trialsClinical trial,After some initial hesitation,Western pharmaceutical manufactures are,rushing,to the,Peoples Republic of China,to establish a“,presence,”just a few years ago.,This meant opening an,office,in Beijing or Shanghai to sell their internationally approved products to the growing Chinese market.,This meant opening,中国制药行业的外资情况,尽管存在着文化、种族和法规的差异，越来越多的外国公司开始在中国进行多个实验中心的三期临床实验。,经历了短暂的犹豫之后，就在这些年，西方制药公司纷纷涌入中国建立了其“基地（办事处）”。这就意味着在他们在北京、上海开辟一个办事处向不断增长的中国市场销售他们国际认证的产品。,中国制药行业的外资情况 尽管存在着,No longer.If you are serious about the Chinese market,you have to come here as a,full pharmaceutical company,says Dr.Ross Horsburgh,regional medical director for Beijing-based Zeneca SinoPharm Development Consulting Company,a,joint venture,between Britain s Zeneca Pharmaceuticals and China s Sino-Pharm.You can t come here just as a sales outfit or just as a distribution channel.,The basic means of Chinas absorption of foreign investments,Sino-foreign joint ventures,Cooperative businesses,Exclusively foreign-owned enterprises,Joint exploitation,Foreign-funded share-holding companies,New types of foreign investment,The basic means of Chinas abs,中国制药行业的外资情况,现在的情况不是这样的了。“如果你对中国市场还心存疑虑的话，你可以以一个完整的制药公司来中国。”,Ross Horsburgh,这样说，他是捷利康中国医药集团发展顾问公司北京区制药总监。该公司是英国捷利康和中国医药集团总公司共同设立的合资企业。他还说到：“你到中国来已经不能仅仅作为一个销售组织或者分散产品的渠道了。”,中国制药行业的外资情况 现在的情况不是这样的了。“如果你,When MDS Harris,the Canadian-owned contract research organization,opened an office in China in 1993,the,interest,by US and European pharmaceutical companies in doing something more than a small Phase IV trial to meet China s minimal licensing criteria was modest at best,says Dr James McClurg,the CROs President and Chief Executive Officer.,When MDS Harris,the Cana,In the past two years,the interest has increased exponentially,he says.Today,the interest in China,and in conducting clinical trials in China to the Western standard,is quite frankly overwhelming.Its a very broad interest by major drug companies everywhere in the world,he says.,药学英语电子教案课件,Name card:,Chairman:executive chairman,Stockholder;,CEO:chief executive office,Inspector;Director,Manager:general manager,vice manager,Name card:Chairman:executiv,中国制药行业的外资情况,“,当加拿大国有契约研究组织（,CRO,）,MDS Harris,于,1993,年首次在中国设立办事处以来，美国和欧洲的制药公司开始对此投入的关注远远超出了仅仅是在中国做一些简单的四期临床实验以符合中国市场的最低要求”。作为,CRO,的主席和首席执行官（,CEO,）的,James McClurg,博士说。“在过去的两年，这样的关注迅速扩大。今天，在中国进行的临床实验水平，坦率地讲，已经超过了西方标准。这将是世界各大制药企业广泛关注的事实。”,中国制药行业的外资情况 “当加拿大国有契约研究组织（CRO,Back in 1980,Tokyos Otsuka Pharmaceutical created the first Sino-foreign pharmaceutical joint venture:China Otsuka Pharmaceutical.It was followed in 1982 by Swedens Pharmacia,which set up the first European joint venture:Wuxi Sino-Swed Pharmaceutical.,Back in 1980,Tokyos Ots,By 1995,1500 pharmaceutical joint ventures were registered with foreign companies in China,according to the Chinese Pharmaceutical Market Guide 1997,published by PJB Publications.,中国制药行业的外资情况,追溯到,1980,年，日本大冢制药有限公司在中国创立了第一个中外合资制药企业：中国大冢制药有限公司。紧接着，,1982,年，瑞典法玛西亚制药公司在中国建立了第一个欧洲合资企业：无锡中国瑞典制药公司。到,1995,年，根据,PJB,出版的,1997,年中国制药市场指南统计：在中国已经有,1500,家中外合资制药企业注册。,中国制药行业的外资情况 追溯到1980年，日本大冢制,Eighteen of the top 20 global pharma-ceutical,giants,have entered into these arrangements.Germanys Bayer has nine joint ventures in China,with a total investment of US$160 million investment.Switzerland Roche has seven,and a US$130 million investment,.,Eighteen of the top 20,中国制药行业的外资情况,全球,20,家制药巨头中的,18,家已经都进入了中国市场，德国的拜尔制药公司已经在中国建立了,9,家合资企业，总投资大约在,160,000,000,美金。瑞士的罗氏制药有限公司在中国建立了,7,家合资企业，总投资大约是,130,000,000,美金。,中国制药行业的外资情况 全球20家制药巨头中的18家已,世界著名药厂,1.,辉瑞（,PFIIER,）,强生（,johnson&johnson,）,西安杨森 上海强生制药有限公司,10.,拜尔（,BAYER,）,4.,默克制药（,MERCK),5.,诺华,NOVARTIS,：北京诺华制药有限公司,6.,雅培,:,上海雅培制药有限公司,7.,阿斯利康制药有限公司,8.,礼莱,LILLY,9.,施贵宝（,SQUIBB,）,3.,葛兰素史克制药,(GLAXO-SHICO,世界著名药厂 1.辉瑞（PFIIER）强生（johnso,世界著名药厂标志,世界著名药厂标志,世界著名药厂标志,世界著名药厂标志,药学英语电子教案课件,世界著名药厂标志,世界著名药厂标志,